XLH Patient Says new Drug is Giving Her Hope for the Future

At 55 years old, Linda Mozzone says she’s getting a second chance at life, all because of a new drug from Indiana University School of Medicine.

“It has been two-and-a-half years now, and it has changed my life,” said Mozzone, who lives with her husband and son outside of Chicago, Illinois. Mozzone was diagnosed with X-linked hypophosphatemia, or XLH, at age two. XLH is a phosphate-wasting disease that causes rickets and osteomalacia, or softening of the bones. 

While XLH is typically inherited, Mozzone’s case was spontaneous. There is a 50 percent chance her children would have the condition, but she says she’s thankful she did not pass it down to her son.


To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.